---
layout: default
title: Apis Mellifera Araneus Diadematus Barium Carbonate
parent: 僅模型預測 (L5)
nav_order: 380
evidence_level: L5
indication_count: 0
---

# Apis Mellifera Araneus Diadematus Barium Carbonate
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Ingredient Homeopathic Complex (20 Components): Repurposing Evaluation Cannot Be Completed

## One-Sentence Summary

This submission contains a 20-ingredient homeopathic combination formula encompassing botanical extracts, mineral salts, animal-derived venoms, and thyroid material.
The TxGNN model returned **no repurposing predictions** for this product, most likely because the complex multi-ingredient composition could not be resolved to a single DrugBank entry.
No evidence-based evaluation can be completed under the current data state.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Unknown — no approved indication on record; product is not registered |
| Predicted New Indication | None — TxGNN returned zero candidates |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A — pipeline unable to generate candidates |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why No Prediction Was Generated

The TxGNN knowledge-graph pipeline requires a valid DrugBank ID as the anchor node to traverse disease–drug relationships. Because this submission is a 20-component homeopathic combination with no resolvable DrugBank ID, the pipeline could not place the product in the knowledge graph and therefore produced zero repurposing candidates.

The 20 listed ingredients span four distinct categories:

| Category | Ingredients |
|----------|-------------|
| Animal-derived | Apis mellifera (honeybee), Araneus diadematus (garden spider), Vipera berus (viper venom), Thyroid (unspecified) |
| Botanical | Claviceps purpurea, Equisetum hyemale, Fucus vesiculosus, Fumaria officinalis, Horse chestnut, Juglans cinerea, Myosotis arvensis, Nasturtium officinale, Phytolacca americana, Scrophularia nodosa, Smilax ornata, Teucrium scorodonia |
| Mineral salts | Barium carbonate, Potassium chloride, Potassium iodide, Sodium sulfate |
| Fungal | Claviceps purpurea sclerotium (ergot) |

Even if individual ingredients were mapped separately, homeopathic preparations are typically prepared at extreme dilutions where conventional pharmacokinetic and mechanistic assumptions do not apply — further limiting the utility of a knowledge-graph approach for this product class.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## US Market Information

This product has no US NDA filings on record and is not marketed. No authorization table can be generated.

---

## Safety Considerations

Please refer to the manufacturer's package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN pipeline requires a single, resolvable DrugBank entity as input; this multi-ingredient homeopathic combination cannot satisfy that requirement, and zero repurposing candidates were produced. Without predictions, regulatory data, or safety information, no evaluation pathway can be advanced at this time.

**To proceed, the following is needed:**

- **Confirm product identity**: Determine whether this ingredient list corresponds to a known branded homeopathic product (e.g., a Heel or BHI formulation such as Lymphomyosot) and obtain the brand name and country-of-origin regulatory filing.
- **Obtain original indication**: Retrieve the approved indication from the originating country's regulatory authority.
- **Resolve DrugBank mapping**: Attempt individual-ingredient mapping to identify which components (if any) carry their own DrugBank IDs and can be run through TxGNN independently.
- **Obtain safety data**: Download the manufacturer's package insert and extract warnings, contraindications, and drug interactions.
- **Re-run pipeline**: Once at least one ingredient is mapped to a valid DrugBank ID, re-submit as a single-ingredient query to generate TxGNN predictions.
- **Clinical plausibility review**: If a predicted indication emerges, convene a pharmacology review to assess whether the homeopathic dilution factor is consistent with the proposed mechanism.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

